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Paris, France, 20 Équipe ATIP/AVENIR, Inserm, UMR 738, Paris, France
Abstract
The CoPanFlu-France cohort of households was set up in 2009 to study the risk factors for infection by the pandemic
influenza virus (H1N1pdm) in the French general population. The authors developed an integrative data-driven approach to
identify individual, collective and environmental factors associated with the post-seasonal serological H1N1pdm geometric
mean titer, and derived a nested case-control analysis to identify risk factors for infection during the first season. This
analysis included 1377 subjects (601 households). The GMT for the general population was 47.1 (95% confidence interval
(CI): 45.1, 49.2). According to a multivariable analysis, pandemic vaccination, seasonal vaccination in 2009, recent history of
influenza-like illness, asthma, chronic obstructive pulmonary disease, social contacts at school and use of public transports
by the local population were associated with a higher GMT, whereas history of smoking was associated with a lower GMT.
Additionally, young age at inclusion and risk perception of exposure to the virus at work were identified as possible risk
factors, whereas presence of an air humidifier in the living room was a possible protective factor. These findings will be
interpreted in light of the longitudinal analyses of this ongoing cohort.
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Introduction
Since the novel influenza A/H1N1 pandemic virus (H1N1pdm)
started spreading in April 2009, several studies have identified risk
factors for H1N1pdm infection in the community such as young
age [1–3], ethnicity [2,4], male gender [4], urban area [5], low
pre-epidemic serologic titer [3–5], use of public transport [4],
household size [6–9] and presence of an index case in the
household [3], especially if it was a child [10].
The CoPanFlu-France cohort, which has previously been
described elsewhere [11], aimed at studying the risk of influenza
infection as a complex combination of biological characteristics
(including immunity), individual or collective behaviors and
environmental context. This integrative approach consists in
comprehensively collecting and analyzing epidemiological data on
subjects and their environment as well as biological samples
[12,13].
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Inclusion of households started in December 2009, at the end of
the first H1N1pdm season in metropolitan France. We studied
factors associated with the post-pandemic H1N1pdm titer from
blood samples collected at inclusion. Previous studies showed that
post-pandemic titer was linked to age classes [2,14–20] and to
pandemic vaccination status [21]. Relying on the massive amount
of data collected at entry in the cohort, we tried to find other
independent associations with this titer. In a complementary study,
we carried out a nested case-control analysis in these subjects to
identify risk factors for probable infection during the first
H1N1pdm season.
Materials and Methods
Study design
This study relies on 601 households (1450 subjects) included in
the study between December 2009 and July 2010, according to a
stratified geographical sampling scheme in the French general
population. More details on this sampling procedure, the
representativeness of the sample and the global study design are
available in a previous publication [11]. A total of 575 households
(96%) were included after the first pandemic season (September 7
to December 27, 2009 [22]).
During the inclusion visit, nurses collected detailed data from all
subjects with questionnaires and blood samples for serological
analyses. As 73 of these samples (5.0%) were either too difficult to
obtain (young children especially) or of insufficient quality or
quantity to be analyzed, the analyses presented here focused on
the 1377 subjects for whom haemagglutination inhibition (HI) titer
was measured.
Variables
HI assay. The outcome measure was the post-seasonal HI
titer, measured from blood samples collected at inclusion. A
standard HI technique was adapted to the detection and
quantification of antibodies to H1N1pdm. HI assay was conducted
in a Bio-Safety Level 3 laboratory using 5.33 haemagglutinating
units of non-inactivated antigen [14]. The antigen used was made
of a dilution of cell culture supernatant of a H1N1pdm strain
(strain OPYFLU-1 isolated from a young patient returning from
Figure 1. Mean duration of daily meetings (in minutes) of CoPanFlu subjects according to location, age of subjects (±6 months)
and age of contacts (±6 months), with 3-year smoothing for both axes.
doi:10.1371/journal.pone.0060127.g001
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Mexico in early May 2009) [23]. A final volume of 75 ml was used,
including 25 ml of serum dilution, 25 ml of virus suspension, and
25 ml of a 1% RBC suspension in PBS (v/v: 0.33%). The HI titer
was determined as the highest dilution providing clear inhibition of
haemagglutination in two independent readings [24]. All exper-
iments were conducted using serial dilutions (1/10–1/1280) of
heat-inactivated sera, group O human erythrocytes (French Blood
Bank). All experiments were performed with same negative and
positive controls [25] and with a serum agglutinating activity
control. All steps of HI assay were performed on Eppendorf
epMotion working stations.
Definition of infections (case-control analysis). Though
some authors previously carried out risk factors analyses after
defining cases as subjects with HI titer $1/40 [2,26], we chose in
our main analysis a higher threshold for our definition as titers
between 1/40 and 1/80 were likely to result from a cross-reaction.
We therefore defined cases as subjects with HI titer $1/80 and all
other subjects were considered as controls. In two sensitivity
analyses, we additionally defined (i) controls as subjects with HI
titer ,1/40 and (ii) cases as subjects with HI titer $1/80 who
reported an influenza-like illness (ILI) during the pandemic season
and controls as subjects with HI titer ,1/40 and no history of ILI.
All pandemic vaccine recipients were excluded from these
analyses.
Covariates. All covariates used in the analysis are listed
elsewhere [11] and detailed in Tables S1–S6 in File S1. The
relation with HI titer was studied for 310 covariates, gathered
according to 6 main dimensions: 1) sociodemographic character-
istics, smoking habits and medical history, 2) vaccination and
preventive measures against the virus, 3) indoor housing, 4)
attitudes, beliefs and risk perception, 5) nature of meetings with
other people and characteristics of contacts and 6) ecological data
regarding the surrounding environment. For dimensions 1 to 5, we
used data collected from questionnaires completed by the
household members, with the help of the visiting nurse. For
geographic data, we geocoded the addresses of households and
used information on the surrounding demographic and socio-
economic context provided by the French Institut national de la
statistique et des études économiques (Insee) regarding statistical
block groups of about 2000 inhabitants (IRIS) [27].
Definitions and coding. Some quantitative covariates were
either dichotomized or log-transformed to enhance log-linearity of
the studied relation (see supplementary material for details). Age
was studied as a quantitative covariate. Subjects reported medical
history and vaccinations with the help of their health records. We
defined history of ILI as fever $37.8uC and cough and/or sore
throat without another known cause [28] between September 7,
2009 and the date of inclusion. This covariate was excluded from
the case-control analysis, which focused on possible risk factors.
Daily frequency of hand washing was reported for the day before
inclusion. For covariates describing smoking habits and preventive
measures against the virus, characteristics of other members of the
household was studied as an individual explanatory covariate (as a
mean for quantitative covariates and as a proportion for binary
covariates). Covariates regarding attitudes, beliefs and risk
perception were collected from all subjects aged over 15 years
with a dedicated questionnaire. Subjects were proposed affirma-
tive sentences and were asked for all of them if they totally agreed,
partly agreed, partly disagreed or totally disagreed. These answers
were dichotomized (agree/disagree).
A contact was defined as someone the subject either spoke with
(at least 3 words) or had a physical contact with. All subjects
reported meetings with their contacts during a 3-day period
ending the day before inclusion. Duration and location of meetings
were collected, as well as age of contacts. In order to study
meetings as covariates likely to be associated with the HI titer, we
summed the individual durations of daily meetings according to
their location (home, work, transports and at school) and to the age
of contacts respectively. Summed durations of meetings were log-
transformed (with an imputed value of 0.01 minute for subjects
reporting a null summed duration of meetings). No information
was collected on simultaneity of meetings, and the total reported
duration of meetings was additional (e.g., a 10-minute meeting
with 3 contacts simultaneously accounted for 30 minutes of
meeting).
Statistical methods
All collected covariates likely to be associated with post-seasonal
elevated HI titer were studied. Comparison tests between
subgroups were Fisher’s exact test (for binomial covariates) and
Kruskal-Wallis rank sum test (for continuous covariates).
Estimation of geometric mean titers (GMTs). GMTs
were estimated for HI assays with the use of regression models for
interval-censored data [29,30] accounting for the within-household
correlation. Post-stratification was used to compute representative
post-seasonal GMT in the French general population. Calculation
and use of sampling weights were detailed elsewhere [11].
We defined the ‘‘GMT ratio’’ (GMTR) as the multiplicative
factor between the GMT in exposed versus non-exposed (for a
binary covariate) or for each unit increase (for a quantitative
covariate).
Control for confounding. As age and pandemic vaccination
status had an important impact on the serological titer, GMTR
was systematically adjusted on these major confounders in all
univariable analyses. For analyses regarding environmental
characteristics of the bedroom and of the IRIS, correlations were
Figure 2. Geometric mean titer (GMT) in relation to age and
pandemic vaccination in the general population. Red curve:
pandemic vaccine recipients (N = 157); green curve: subjects with no
pandemic vaccine and no history of influenza-like illness (ILI) (N = 1,067);
blue curve: subjects with no pandemic vaccine and history of ILI
(N = 95); gray curve: all subjects (N = 1,377). Smoothed GMTs are
estimated for subjects aged between 5 years below and 5 years above
the indicated age. GMTs are estimated for each interval based on all
subjects in the interval and post-stratified with respect to the general
population structure.
doi:10.1371/journal.pone.0060127.g002
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considered at these two levels respectively. Analyses of contacts
were adjusted on the proportion of weekend days in the 3-day
period.
Case-control analysis. Risk factors for infection were
studied with the use of alternating logistic regression to model
the pairwise odds ratios (ORs) between responses of subjects living
in the same room, the same household or the same IRIS [31]. All
univariable analyses were adjusted on age and control for
confounding was carried out with the same adjustment measures
as those used for the GMT analysis.
Model selection. The same selection process was used for
both analyses. GMTRs and ORs were estimated for all covariates
individually. Since a large number of covariates were tested, we
adjusted the p-value to control the alpha inflation associated with
multiple hypothesis testing and to account for the false discovery
rate (FDR) for all covariates [32].
Table 1. Multivariable models for geometric mean titer ratio in CoPanFlu-France subjects at inclusion.
All subjects (N = 1377)
Covariate GMTR 95% CI P
Pandemic vaccine recipient (B) 1.77 1.56, 2.01 ,0.0001
Seasonal vaccine recipient (2009) (B) 1.11 1.01, 1.21 ,0.03
History of ILI for season 2009–2010 (B) 1.31 1.15, 1.49 ,0.0001
Asthma (B) 1.17 1.01, 1.37 ,0.05
Chronic obstructive pulmonary disease (B) 1.28 1.05, 1.56 ,0.02
History of smoking (B) 0.93 0.88, 0.99 ,0.03
Duration of meetings at school (L) 1.03 1.01, 1.04 ,0.01
Proportion of workers using public transports to go to work (Q) 1.45 1.00, 2.10 ,0.05
Subjects without pandemic vaccination (N = 1207)
Covariate GMTR 95% CI P
Seasonal vaccine recipient (2009) (B) 1.30 1.13, 1.48 ,0.001
History of ILI for season 2009–2010 (B) 1.11 1.03, 1.20 ,0.01
Chronic obstructive pulmonary disease (B) 1.23 1.02, 1.48 ,0.03
History of smoking (B) 0.92 0.86, 0.98 ,0.02
Duration of meetings at school (L) 1.03 1.01, 1.04 ,0.001
Proportion of workers using public transports to go to work(Q) 1.46 1.01, 2.11 ,0.05
Pandemic vaccine recipients (N = 168)
Covariate GMTR 95% CI P
Age at inclusion (per 10 years) (Q) 0.91 0.86, 0.96 ,0.001
History of ILI for season 2009–2010 (B) 1.62 1.39, 1.90 ,0.0001
Months since pandemic vaccination (B) 0.84 0.79, 0.90 ,0.0001
(B): binary covariates; (Q): quantitative covariates; (L): log-transformed quantitative covariates; GMTR: geometric mean titer ratio; CI: confidence interval.
doi:10.1371/journal.pone.0060127.t001
Table 2. Multivariable models for the case-control analysis of risk factors for probable infection in CoPanFlu-France unvaccinated
subjects.
Subjects without pandemic vaccination, 171 cases with HI titer $1/80, 1,036 controls with HI titer ,1/80
Covariate OR 95% CI P
Age at inclusion (per 10 years) (Q) 0.87 0.77, 0.98 ,0.02
Chronic obstructive pulmonary disease (B) 2.89 1.41, 5.92 ,0.01
Asthma (B) 2.41 1.32, 4.42 ,0.01
Duration of meetings at school (L) 1.11 1.03, 1.19 ,0.01
Air humidifier in the living room (B) 0.64 0.41, 0.99 ,0.05
Believes that not going to work protects against H1N1pdm (B) 1.61 1.02, 2.53 ,0.05
Proportion of workers using public transports to go to work (Q) 11.2 2.08, 60.0 ,0.01
Pairwise odds ratios between cases living in the same household 3.31 1.82, 6.02 ,0.0001
(B): binary covariates; (Q): quantitative covariates; (L): log-transformed quantitative covariates; OR: odds ratio; CI: confidence interval.
doi:10.1371/journal.pone.0060127.t002
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All covariates with an adjusted P,0.30 in univariable analyses
were included in a multivariable analysis. Thirty datasets were
imputed via multiple imputations by chained equations (MICE)
[33]. Covariates related to attitudes, beliefs and risk perception for
children were sampled from subjects over 15 years in the same
household.
The criterion for model selection was the mean residual sum of
squares with 10-fold cross-validation – aimed at avoiding over-
fitting and controlling FDR – run over the 30 imputed datasets
and considering only models with P,0.05 for all covariates.
Resulting coefficients and standard errors were combined to
obtain the reported results [34]. Additional multivariable models
were estimated separately stratified by pandemic vaccination
status.
Statistical analyses were performed with R version 2.15. We
estimated GMTRs with the function ‘‘survreg’’ (package ‘‘surviv-
al’’ version 2.36). Multiple imputation was done with the package
‘‘mice’’ and we ran alternating logistic regression with the package
‘‘orth’’.
Results
Descriptive data
Characteristics of the 1377 subjects are given in Tables S1–S6
in File S1. The median age at inclusion was 43.1 years
(interquartile range (IQR): 20.7, 59.9 years), 38 children were
aged 2 to 5 years and 14 children were aged ,2. A total of 561
subjects (40.1%) had at least one history of chronic disease. History
of ILI since the beginning of the pandemic wave was reported in
99 subjects (7.5%). For the 3 previous seasons, the proportion of
ILI ranged from 7.3% to 19.1%. History of smoking was reported
in 544 subjects (39.5%).
The proportion of pandemic vaccine recipients was 12.2%. The
median time since pandemic vaccination was 3.2 (IQR: 1.7, 5.2)
months. Pandemic vaccine recipients were younger than seasonal
vaccine recipients: 46.4 (17.1, 63.0) vs. 63.8 (IQR: 50.4, 72.0) years
(P,0.0001). Nine hundred and thirteen subjects (66.3%) were
living in a house and the median area per inhabitant was 36.7
(IQR: 25.0, 52.5) m2.
Detailed data on meetings was collected in 1360 out of the 1377
subjects. The median number of reported daily meetings was 6
(IQR: 3, 10) and the median summed duration was 963 (IQR:
503, 1646) mn/day, with significant differences according to age
groups and locations (Figure 1). Subjects aged less than 15 years
had a higher daily duration of meetings than older ones: 1847
(IQR: 1147, 2564) mn vs. 848 (IQR: 440, 1378) mn, P,0.0001.
Children at school reported a large amount of meetings with
children of the same age. Working adults aged 20 to 60 years had
many meetings with persons of their age. At home, subjects had
meetings with people of their age and with persons from the
previous or next generation.
GMT estimates (post-stratified estimates)
Raw measured HI titer was $1/20 for 1319 subjects (95.8%),
$1/40 for 832 subjects (60.4%), $1/80 for 259 subjects (18.8%)
and $1/160 for 50 subjects (3.6%). After post-stratification the
estimated proportions were 95.3% for $1/20, 59.0% for $1/40,
16.1% for $1/80 and 2.8% for $1/160.
The estimated GMT for the general population was 47.1 (95%
confidence interval (CI): 45.1, 49.2]) It was higher in pandemic
vaccine recipients (80.3 (95% CI: 69.8, 92.5) vs. 44.2 (95% CI:
42.4, 46.0) for unvaccinated subjects with no history of ILI and
58.7 (95% CI: 51.7, 66.6) for unvaccinated subjects with history of
ILI) and in subjects aged ess than 5 years (55.2 (95% CI: 49.2,
62.0) vs. 45.7 (95% CI: 43.8, 47.6) for older ones). Figure 2 gives
an overview of the estimated post-stratified GMT with respect to
the general population structure, in relation to pandemic
vaccination status, history of ILI and age of subjects.
Factors associated with the GMT
All univariable GMTR estimates are listed in Tables S1–S6 in
File S1. A total of 40 covariates with adjusted P,0.30 were
retained in the multivariate analysis.
Selected multivariable models are listed in Table 1. Considering
all the subjects (irrespective of the vaccination status), the final
model retained (i) pandemic vaccination, 2009 seasonal vaccina-
tion, history of ILI for season 2009–2010, asthma, COPD,
duration of meetings at school and IRIS proportion of workers
using public transports as covariates associated with a higher
GMT, and (ii) history of smoking as covariate associated with a
lower GMT.
Considering the 1,207 subjects without pandemic vaccination,
‘‘asthma’’ was the only covariate that did not remain in the final
model. Considering the 171 pandemic vaccine recipients, history
of ILI remained in the model, while older age at inclusion and
time since pandemic vaccination were associated with a lower
GMT.
Case-control analysis
The 1,207 unvaccinated subjects were included in this analysis,
171 as cases and 1,036 as controls. The proportions of subjects
with a history of ILI were 18.0% in cases and 6.5% in controls
(P,0.0001). The final multivariable model retained (i) COPD,
Figure 3. Weekly incidence of influenza-like illnesses (ILIs) in France (French General Practitioner Sentinel network [22]) and weekly
pandemic vaccinations in CoPanFlu subjects, weeks 2009–26 to 2010–08. Blue bars (left scale): national weekly incidence of ILIs; red bars
(right scale): number of weekly pandemic vaccinations in CoPanFlu subjects.
doi:10.1371/journal.pone.0060127.g003
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asthma, duration of meetings at school, proportion of workers
using public transports and belief that not going to work protects
against H1N1pdm as factors associated with a higher risk of
probable infection, and (ii) older age and having an air humidifier
in the living room as factors associated with a lower risk (see
Table 2 for details). Though we estimated pairwise odds ratios
between responses of subjects living in the same room, the same
household or the same IRIS, only the household level was kept in
the final model as the other ones were not significant, OR = 3.31
(95% CI: 1.82, 6.02). Multivariable models for the sensitivity
analyses retained subsets of these factors with no additional factors
(Table S7 and S8 in File S2).
Discussion
Covariates associated with HI titer
Post-pandemic elevated HI titer can be explained by a pre-
pandemic elevated titer, a recent increase in titer due to an
infection by the pandemic virus or to another antigenic stimulation
(e.g., pandemic vaccination), or by any combination of these
different factors. We review our findings in light of other studies on
the same topic.
The global multivariate model including pandemic vaccination
gave information on the association of this factor with the GMT.
Adjustment on this factor in the same model allowed us to study
factors that may have an impact on GMT increase after either
vaccination or infection, whereas stratified analyses according to
this vaccination intended to focus more specifically on factors
associated with other causes of elevated GMT.
We found a lower anti-H1N1pdm GMT in older subjects in the
univariable analysis and in the multivariable model run among
pandemic vaccine recipients. This covariate did not remain in the
other multivariate models mainly because of the adjustment on
duration of contacts at school (age was significantly associated with
the GMT in all models when we excluded this covariate). Older
age was also associated with a lower risk of probable infection in
the case-control analysis.
These results are consistent with other cross-sectional post-
pandemic studies worldwide, including modeling [35] and
serological [14] studies in France, which reported a much higher
infection rate in children and young adults [16,19,20,36–44].
As expected, a reported history of ILI was associated with an
elevated GMT, which indicates that some of these ILIs were
probably caused by H1N1pdm infection. Though this factor lacks
sensitivity and specificity to be considered as a good correlate of
infection, its coefficient in selected multivariable models gives
more information on the relative role of infections among all
causes leading to a GMT increase. Its association with the GMT
in vaccinated subjects indicates that the GMT was also caused by
H1N1pdm infections. Indeed, as most vaccinations occurred at the
end of the pandemic course (Figure 3), we could not distinguish
whether the increased GMT in vaccine recipients was caused by
vaccination itself or by previous infection.
Asthma and COPD were associated with a higher GMT and
possible risk factors in the case-control analysis. Asthmatics may
have increased susceptibility for H1N1pdm infection [45], possibly
because of alterations in the airway architecture [46,47] and
impairment of innate immunity [47]. Another hypothesis to
explain a higher GMT in subjects with such medical conditions,
regardless of their susceptibility to infection, would be a more
severe illness [48] involving a greater immune response [49].
We found that smoking history was associated with a lower
GMT. Although several studies already found an association
between cigarette smoking and risk to contract influenza infection
[50–52], smokers have a well-known diminished serological
response to influenza infection or vaccination [52], the immuno-
suppressive mechanism is still unclear [53–56].
Seasonal vaccination for any season since 2006–2007 was
associated with an increase in the GMT, maybe because of a cross-
reactive immune response with seasonal vaccination H1N1 strains
[57]though studies investigating this association were all incon-
clusive [3,58]. Another hypothesis would consider that elevated
post-seasonal titer might be a consequence of an increased risk of
pandemic infection in seasonal vaccine recipients [59], though
conflicting results were reported about this association [60–64].
In covariates related to the environmental characteristics of the
housing, only the association between presence of an air
humidifier in the living room and lower risk remained in the
case-control multivariable model, which may be consistent with
the possible impact of relative humidity on influenza aerosol
transmission [65,66].
The multivariable analysis retained no covariate related to
attitudes, beliefs and risk perception, except the belief that not
going to work may protect against H1N1pdm infection, associated
with a higher risk in the case-control analysis. We have no clear
interpretation for this finding, except that this covariate may be a
correlate of more general characteristics of risk perception, which
affect the transmission patterns of pandemic influenza.
Increasing GMT and a higher risk of probable infection
associated with duration of meetings at school were not surprising
since schools are identified as places with high meeting rates
between influenza susceptible subjects [67]. Interestingly, we did
not find a significant association of GMT with daily duration of
meetings with children younger than 10 years old regardless of
location, suggesting that school favors transmissions by a particular
pattern of contacts or environmental characteristics [67,68].
The multivariable analysis retained no covariate related to the
characteristics of the surrounding area, except the proportion of
workers using public transportation to go to work, which also
appeared as a possible risk factor.
The important pairwise OR we found in the case-control
analysis for subjects living in the same household suggests a
common environmental exposure or susceptibility for these
subjects who often belong to the same family, or more probably
an elevated intra-household secondary attack rate (estimated 4 to
37% in previous household studies [10]).
Limitations
Though households were sampled in the general population,
some households refused to participate, which may induce a
selection bias. However, comparisons with French population
census data suggest that this bias was controlled [11], and post-
stratification of the GMT by age and vaccination status with respect
to the French population structure did not modify the results
significantly. We did not post-stratify our estimations of the GMTR,
as the choice of the auxiliary covariates used to adjust the sampling
weights could have induced important changes in the standard error
of our estimates leading to spurious associations [69].
The timeline of inclusion may have induced recall or reporting
biases. The cohort was designed to include households before the
2009 pandemic season and to follow-up subjects during the
influenza season. As inclusions were delayed, data regarding ILIs
were collected retrospectively and recall bias may be important in
subjects with late inclusion. Moreover, we found a decreasing
GMT according to time since vaccination in pandemic vaccine
recipients, and we cannot exclude an antibody loss in the months
following an infection, although we did not find any association
between GMT and date of inclusion in unvaccinated subjects.
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Such limitations may have biased the association between GMT
and other covariates.
In the case-control analysis, cases were defined serologically, yet
we know that an elevated titer can sometimes be explained by
cross-reactions, especially in the elderly [16], and that infected
subjects can show a low titer a few months after infection [70].
This lack of specificity and sensitivity to identify infections must be
considered in light of the sensitivity analyses results, which often
showed similar results with different case definitions.
Another limitation may be linked to the amount of data
collected. Though we controlled this FDR with the use of specific
procedures, multiple testing of hundreds of covariates results in an
important risk of finding spurious associations, due to the alpha
inflation phenomenon.
Because of these limitations, our analysis must be understood as
a hypothesis generating study aimed at identifying the possible role
of many factors that would probably not have been studied
otherwise. Further studies would be necessary to confirm the
impact of these factors and their implications for the control of
influenza.
Conclusion
We used a data-driven framework to carry out an exploratory
analysis of potential relevant risk factors for infection. This
hypothesis generating tool relying on an integrated approach
allowed us to highlight the possible impact of previously unknown
factors from several dimensions usually studied separately, such as
presence of an air humidifier (indoor environment), duration of
meetings at school (social contacts), characteristics of the local
population or risk perception. Additional data is being collected
and analyzed in this ongoing cohort. The longitudinal analysis of
these households will permit integrative analyses of complex
phenomena such as individual, collective and environmental risk
factors for infection, routes of transmission, or determinants of the
immune response to infection or vaccination.
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